News | October 08, 2010

Study Shows Bivalirudin Improves Survival in AMI

October 8, 2010 – New data from the HORIZONS-AMI trial shows that administering the anticoagulant bivalirudin (Angiomax) enhances survival in heart attack patients undergoing angioplasty after three years. The results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 symposium in Washington, D.C.

The study compared bivalirudin to the use of heparin plus a GP IIb/IIIa inhibitor. The data also showed that a drug-eluting stent (paclitaxel) was as safe and more effective than a bare-metal stent.

“The results at three years, representing the final report from the HORIZONS-AMI trial, are consistent with and extend the two-year data that we reported last year at TCT,” said Gregg W. Stone, M.D., professor of medicine at Columbia University College of Physicians and Surgeons, director of cardiovascular research and education at the Center for Interventional Vascular Therapy at New York Presbyterian Hospital/Columbia University Medical Center and co-director of the medical research and education division at the Cardiovascular Research Foundation. Stone is the principal investigator of the HORIZONS-AMI trial.

“The data demonstrate that use of bivalirudin alone, as opposed to a combination of heparin and a GP IIb/IIIa inhibitor, can save lives,” Stone said. “In addition, a significant reduction in second heart attacks has emerged over time in patients treated with bivalirudin.”

After three years, treatment with bivalirudin resulted in:

• A 36 percent reduction in major bleeding and a 24 percent reduction in re-infarction, with nonsignificantly different rates of stent thrombosis, target vessel revascularization (TVR) and stroke.

• A 44 percent reduction in cardiac mortality and a 25 percent reduction in all-cause mortality, the latter representing 18 lives saved per 1,000 patients treated with bivalirudin.

In addition, at three years, the implantation of a paclitaxel-eluting stent resulted in:

• A significant 40 percent reduction in ischemic target lesion revascularization (TLR), with preservation of the gains achieved within the first year over time.

• Nonsignificantly different rates of all-cause and cardiac mortality, re-infarction and stent thrombosis.

For more information: www.crf.org

Related Content

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Overlay Init